Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 38.0%

15 Feb 2026, 20:20 by Sarita Garza · The Markets Daily

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) was the recipient of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 7,664,016 shares, an increase of 38.0% from the January 15th total of 5,554,802 shares. Currently, 12.6% of the shares of the company are sold short. Based on an average daily volume of 1,138,207 shares, the days-to-cover ratio is currently 6.7 days. Based on an average daily volume of 1,138,207 shares, the days-to-cover ratio is currently 6.7 days. Currently, 12.6% of the shares of the company are sold short.

Monte Rosa Therapeutics Stock Down 3.1%

Monte Rosa Therapeutics stock traded down $0.58 during trading hours on Friday, hitting $17.92. 743,196 shares of the company traded hands, compared to its average volume of 1,052,130. Monte Rosa Therapeutics has a 1-year low of $3.50 and a 1-year high of $25.77. The firm has a market cap of $1.17 billion, a P/E ratio of 56.00 and a beta of 1.61. The firm’s 50-day simple moving average is $19.52 and its two-hundred day simple moving average is $12.64.

Insiders Place Their Bets

In other news, CEO Markus Warmuth sold 5,466 shares of Monte Rosa Therapeutics stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $23.49, for a total value of $128,396.34. Following the completion of the transaction, the chief executive officer directly owned 618,937 shares of the company’s stock, valued at approximately $14,538,830.13. The trade was a 0.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Several hedge funds have recently modified their holdings of GLUE. Nantahala Capital Management LLC acquired a new stake in shares of Monte Rosa Therapeutics in the fourth quarter valued at $909,000. The Manufacturers Life Insurance Company raised its holdings in shares of Monte Rosa Therapeutics by 13.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 134,674 shares of the company’s stock worth $2,147,000 after purchasing an additional 16,291 shares in the last quarter. Advisory Research Inc. acquired a new stake in Monte Rosa Therapeutics during the fourth quarter valued at approximately $991,000. Rafferty Asset Management LLC bought a new stake in Monte Rosa Therapeutics during the fourth quarter worth approximately $1,057,000. Finally, Charles Schwab Investment Management Inc. grew its position in Monte Rosa Therapeutics by 17.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 448,714 shares of the company’s stock worth $7,036,000 after buying an additional 65,446 shares during the last quarter. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on GLUE. Guggenheim increased their price target on Monte Rosa Therapeutics from $16.00 to $34.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Wedbush reaffirmed an “outperform” rating and issued a $37.00 target price on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. TD Cowen reissued a “buy” rating on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Wells Fargo & Company increased their price objective on shares of Monte Rosa Therapeutics from $22.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, January 8th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Monday, December 29th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $31.33.

Check Out Our Latest Analysis on Monte Rosa Therapeutics

About Monte Rosa Therapeutics

(Get Free Report)

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.